Elevidys access in Egypt: the EDA named-patient pathway
How Egyptian families with a child diagnosed with Duchenne muscular dystrophy access Elevidys (delandistrogene moxeparvovec), the AAV-based DMD gene therapy, when local registration and certified-center capability do not match what the prescribing pediatric neurology team has documented.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Quick orientation
Elevidys (delandistrogene moxeparvovec-rokl) is an AAVrh74-based one-time gene therapy delivering a transgene encoding micro-dystrophin, approved by the US FDA on 22 June 2023 for ambulatory pediatric patients aged 4 through 5 with Duchenne muscular dystrophy and a confirmed mutation in the DMD gene, and expanded on 20 June 2024 to ambulatory patients 4 years and older and non-ambulatory patients 4 years and older with a confirmed DMD mutation. It is the first and only gene therapy approved for DMD. The drug is not currently registered with the Egyptian Drug Authority (EDA) for commercial sale, so Egyptian families reach it through the EDA named-patient import framework, with US-source supply coordinated under DSCSA chain-of-custody. Reserve Meds coordinates the US-side sourcing, frozen cold-chain logistics, and the documentation kit the treating pediatric neurology team needs to file with the EDA.
Reserved for you.
Why Egyptian families need Elevidys through the named-patient pathway
Egypt has a large pediatric population (approximately 35 million Egyptians under 18) and a documented hereditary disease profile shaped by consanguinity in Upper Egypt and the rural Delta. Duchenne muscular dystrophy prevalence sits at the global 1 in 3,500 to 1 in 5,000 male birth range; in absolute terms, the Egyptian DMD cohort is in the low thousands. The country's tertiary pediatric neurology infrastructure is concentrated in Cairo (Cairo University's Abu El Reesh Children's Hospital, Ain Shams University Children's Hospital, the National Research Centre, the 57357 Children's Cancer Hospital for hematology cases, and major private centers including Cleopatra Hospital, Dar Al Fouad, and Saudi German Hospital Cairo). Genetic confirmation of DMD has become more accessible through EDA-licensed private genomics labs and the academic medical genetics services at Cairo University and Ain Shams.
The access gap for Elevidys in Egypt has four layers. First, regulatory: Sarepta has not filed Elevidys for EDA commercial registration. Second, certified-center capability: AAV gene therapy infusion requires a pediatric institution with infusion suite, post-infusion ICU backup, and the immunomonitoring infrastructure for the post-infusion period; the count of qualified Egyptian sites is narrow and concentrated in Cairo. Third, eligibility gating: anti-AAVrh74 antibody titer must be below the FDA-labeled threshold, the patient must have a confirmed DMD mutation by next-generation sequencing or MLPA, and the family must accept the boxed-warning context for serious immune-mediated myositis. Fourth, payer reality: at USD 3.2 million list price (approximately EGP 154 million at the 2026 rate range, with rate volatility a meaningful planning variable), no Egyptian public payer reimburses, and private insurers do not cover at this list level. Cash-pay is the operating reality, most often supported by overseas family members in the GCC, North America, or Europe.
The clinical case is time-sensitive: disease-modifying benefit in DMD is greatest before substantial muscle loss has occurred, and Egyptian families who reach us are typically working against an active disease trajectory after years of corticosteroids and supportive care. Exon-skipping therapies (eteplirsen, viltolarsen, golodirsen, casimersen) are not consistently locally available in Egypt, which sharpens the case for the AAV gene therapy where the patient is eligible.
The EDA named-patient pathway for Elevidys
The legal foundation for personal import of unregistered medicines into Egypt is the Egyptian Drug Authority's framework under Law No. 151 of 2019 (which established the EDA as the unified regulatory authority, separating it from the Ministry of Health) and the Pharmacy Law No. 127 of 1955 as amended. The EDA Central Administration for Pharmaceutical Affairs handles personal-import applications for unregistered medicines required for a specific named patient, filed through the institution's import pharmacy and submitted to the EDA's Drug Inspection Department.
For Elevidys specifically, the clinical-justification angle that anchors the application is genetic confirmation plus institutional gene-therapy readiness. The strongest applications consistently document: a confirmed DMD diagnosis with the specific dystrophin gene mutation reported by a named genetics laboratory (NGS report with the deletion, duplication, or point mutation specified); the patient's age (4 years or older) and ambulatory or non-ambulatory status; the baseline North Star Ambulatory Assessment (NSAA) score for ambulatory cases, or baseline upper-limb and respiratory measures for non-ambulatory cases; the anti-AAVrh74 binding antibody titer (must be below the FDA-labeled threshold per the validated assay); the immunosuppression plan for the peri-infusion period (oral prednisone or equivalent starting one day before infusion and continuing for at least 60 days); and the receiving institution's gene therapy infusion capability, pediatric critical care backup, and laboratory infrastructure for the post-infusion creatine kinase, troponin, liver function, and platelet monitoring window.
A complete EDA application includes the clinical justification letter from the treating pediatric neurologist with active Egyptian Medical Syndicate registration, the genetic test report attached as supporting documentation, the anti-AAVrh74 titer result, the proposed dosing plan at the FDA-labeled 1.33 x 10^14 vg/kg delivered as a single intravenous infusion, the destination dispensing facility license under Pharmacy Law No. 127 of 1955, and the chain-of-custody plan describing how the medicine will move from the Sarepta manufacturing facility through the importer to the dispensing pharmacy, including the frozen cold-chain handling at minus 60 degrees Celsius or colder. Approval timelines for routine EDA personal-import cases run 3 to 6 weeks; complex first-time gene-therapy imports can extend to 8 to 12 weeks given the limited institutional precedent.
Where Elevidys gets dispensed in Egypt
The treating-center map for Elevidys in Egypt is narrow because of the AAV gene therapy infusion capability requirement. The institutions most likely to handle an Egyptian Elevidys case are Cairo University's Abu El Reesh Children's Hospital (with its long-standing pediatric neurology subspecialty), Ain Shams University Children's Hospital (Demerdash and Ain Shams Specialized Hospital), the National Research Centre's pediatric program, Cleopatra Hospital Group (notably Cairo Specialized Hospital and Cleopatra Hospital), Dar Al Fouad Hospital in 6th of October City, and Saudi German Hospital Cairo. The 57357 Children's Cancer Hospital handles pediatric hematology and oncology but participates in the broader pediatric gene-therapy conversation through its infrastructure and ICU capability.
The dispensing facility must hold validated frozen storage at minus 60 degrees Celsius or colder, gene therapy infusion suite capability, pediatric critical care backup, and laboratory turnaround for the post-infusion monitoring schedule including weekly creatine kinase, troponin, AST, ALT, total bilirubin, and platelet count for the first 90 days. The receiving institution also carries the peri-infusion corticosteroid course (oral prednisone 1 mg/kg/day or equivalent starting one day before infusion, continuing for at least 60 days, with taper based on clinical and laboratory parameters). For Egyptian families where the originating consultation is at a regional or governorate-level hospital outside Cairo, the practical pathway routes the case to one of the Cairo tertiary centers for the infusion itself, with pre- and post-infusion follow-up coordinated back to the originating center.
Real cost picture for Elevidys in Egypt
US wholesale acquisition cost for Elevidys is approximately USD 3.2 million per single-dose treatment course, the highest list price for any FDA-approved gene therapy as of this page date. At the prevailing USD/EGP rate (approximately 1 USD = 48 EGP in May 2026, with meaningful rate volatility), the cell-product price converts to roughly EGP 154 million. Because the Egyptian pound has shown significant inflation pressure and exchange-rate movement, Reserve Meds quotes Elevidys in USD and accepts wire transfers from any USD-accessible source.
International logistics for the frozen shipper from the Sarepta manufacturing facility to the receiving Egyptian pediatric center add a defined surcharge in the USD 6,000 to USD 18,000 range, with customs pre-clearance through the Egyptian Customs Authority handled in parallel to preserve the validated shipping window. The receiving institution's procedural and inpatient costs (gene therapy infusion suite, peri-infusion corticosteroid course, post-infusion monitoring labs across the first three months, pediatric critical care standby) are the institution's line items, not Reserve Meds'. Reserve Meds' concierge fee is itemised separately on every firm quote.
On the payer side, Egyptian payer behavior at this price point is restrictive. The Universal Health Insurance system, the Health Insurance Organization (HIO), and the Ministry of Health Treatment at State Expense system do not reimburse a USD 3.2 million one-time gene therapy as a standard line item. Private insurers (Allianz Egypt, AXA Egypt, MetLife, Bupa Egypt) assess case by case, with most commercial plans falling short of any meaningful coverage. The dominant funding pattern for Egyptian Elevidys cases is family resources, often supplemented by overseas Egyptian family members in the GCC, North America, or Europe. Egyptian expatriate communities have historically funded high-profile pediatric treatments through cross-border family wires; the single-coordinator model is built for this pattern. We do not promise coverage from any insurer or scheme.
Typical timeline for Elevidys in Egypt
EDA routine processing for personal-import applications is typically 3 to 6 weeks from a complete filing. For Elevidys specifically, first-time gene-therapy imports at any given Egyptian institution can extend to 8 to 12 weeks given the limited precedent. The frozen shipper logistics and customs pre-clearance run in parallel with the regulatory filing. End-to-end from family decision to infusion day, the typical achievable window is ten to sixteen weeks. The anti-AAVrh74 antibody titer test result is the earliest gating event; if the titer is above the FDA-labeled threshold, the case pauses for retest consideration before the frozen shipper is staged. The peri-infusion corticosteroid course starts one day before infusion; the post-infusion monitoring window extends three months actively and longer for the structured pharmacovigilance follow-up.
What your physician needs to provide
For an Egyptian pediatric neurologist prescribing Elevidys through the EDA pathway, the clinical justification letter is the cornerstone of the application. The letter, signed with active Egyptian Medical Syndicate registration, documents the DMD diagnosis with the specific dystrophin gene mutation reported by a named genetics laboratory, the patient's age (4 years or older), ambulatory or non-ambulatory status, baseline functional assessment (NSAA for ambulatory; Performance of the Upper Limb scale and respiratory measures for non-ambulatory), the anti-AAVrh74 binding antibody titer result with the validated assay named, the immunosuppression plan, and the dosing at 1.33 x 10^14 vg/kg delivered as a single intravenous infusion.
The monitoring plan covers weekly creatine kinase, troponin-I, AST, ALT, total bilirubin, and platelet count for the first 90 days, with the boxed-warning vigilance for serious immune-mediated myositis. The treating physician's Medical Syndicate registration number, the dispensing facility's license under Pharmacy Law No. 127 of 1955, and the pharmacy in charge of dispensing complete the package. Adverse event reporting through the Egyptian Pharmaceutical Vigilance Center (EPVC) is referenced in the documentation kit; reporting obligations remain with the prescribing physician and the institution.
Common questions about Elevidys in Egypt
Is Elevidys registered in Egypt? Not at this page date. Sarepta has not filed Elevidys with the EDA for commercial registration. Access for Egyptian families runs through the EDA named-patient personal-import pathway with US-source supply under DSCSA chain-of-custody documentation.
My son is 3 years old. Can he still receive Elevidys? The FDA label is patients 4 years and older. Under-4 cases are off-label and require a separate clinical justification not part of the standard EDA named-patient pathway. The treating pediatric neurology team makes the final eligibility call.
What if the anti-AAVrh74 antibody titer is too high? A titer above the FDA-labeled threshold by the validated assay is an eligibility exclusion at the time of testing. The treating pediatric neurology team determines retest cadence; in some cases titers can fall over time. If the titer remains elevated, the case typically pivots to ongoing corticosteroid therapy and supportive care.
Will Allianz Egypt, AXA Egypt, MetLife, or Bupa Egypt cover the cost? Egyptian private insurers assess multi-million-dollar one-time gene therapies case by case, with most commercial plans falling short of meaningful coverage at this price point. The Universal Health Insurance system, HIO, and the Ministry of Health Treatment at State Expense system do not reimburse a USD 3.2 million one-time gene therapy as a standard line item. We do not promise coverage from any source. Cash-pay funded through family resources is the default operating posture for Reserve Meds-coordinated cases.
Can the medicine be administered outside Cairo? The dispensing facility must hold gene therapy infusion capability, pediatric critical care backup, and validated minus 60 degrees Celsius storage. In practice this concentrates the administration at the tertiary pediatric centers in Cairo. Pre- and post-infusion follow-up can be coordinated with the family's home-governorate neurologist in coordination with the originating Cairo institution.
How does Elevidys interact with corticosteroids my son is already on? Most DMD patients in Egypt are already on long-term prednisone or deflazacort therapy. The peri-infusion corticosteroid plan layers on top of or transitions from the existing regimen, with the treating neurologist managing the overall steroid exposure. The decision sequence rests with the treating team.
What is the boxed-warning serious immune-mediated myositis? Severe muscle weakness, severe creatine kinase elevation, and troponin elevation in the first three months after infusion are the labeled risk for serious immune-mediated myositis. The receiving institution carries the weekly laboratory monitoring through the structured window, with corticosteroid escalation, IVIG, and other immunomodulation as the clinical response pathway. The family receives clear instructions on warning signs and a direct phone line to the institution between visits.
Where Reserve Meds fits in Elevidys cases
Reserve Meds is a US-based concierge coordinator. We do not replace your pediatric neurologist, we do not replace the EDA, and we do not replace the receiving institution's gene therapy and critical care infrastructure. For Elevidys specifically, we orchestrate the US-side sourcing through Sarepta's qualified channel under DSCSA chain-of-custody, build the documentation kit your physician submits to the EDA, coordinate frozen cold-chain logistics with continuous temperature logging into Egypt, pre-stage customs clearance in parallel with regulatory filing, manage the multi-currency funding workflow with overseas family wires, and assign a single named coordinator through the case. The clinical decisions remain with the treating pediatric neurology and gene therapy team; the regulatory authority remains the EDA; the gene therapy delivery remains with the qualified Egyptian institution.
Next step
If your pediatric neurologist has diagnosed DMD in your son and you are weighing the Elevidys cross-border route, the next step is a short waitlist request. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.